Inhaled azithromycin therapy

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 19, Issue 1, 2006, Pages 54-60

  Hickey, Anthony J ^a   Lu, Dongmei ^a   Ashley, Elizabeth Dodds ^b   Stout, Jason ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antibiotic aerosols; Azithromycin; Nebulizers; Particle size

Indexed keywords

AZITHROMYCIN;

AEROSOL; ARTICLE; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; HEARING IMPAIRMENT; HUMAN; LASER DIFFRACTION; LUNG INFECTION; MYCOBACTERIOSIS; NEBULIZER; PARTICLE SIZE; PNEUMOCYSTIS JIROVECI; PROTEIN SYNTHESIS INHIBITION; PSEUDOMONAS AERUGINOSA;

ADMINISTRATION, INHALATION; AEROSOLS; ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; LUNG; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 33645469145     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/jam.2006.19.54     Document Type: Article

References (23)

1. Hickey, A.J. 2005. Pulmonary drug delivery-pharmaceutical chemistry and aerosol technology. In B. Wang, T. Siahaan, and R. Soltero, eds. Delivery Issues in Drug Discovery. John Wiley and Sons, New York (in press).
2. Hickey, A.J. 2004. Summary of common approaches to pharmaceutical aerosol administration. In A.J. Hickey, ed. Pharmaceutical Inhalation Aerosol Technology, 2nd ed. Marcel Dekker, New York, 385-421.
3. Capitano, B., H.M. Mattoes, E. Shore, et al. 2004. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest 125:965-973.
4. Hickey, A.J., M. Kazantseva, L. Garcia Contreras, et al. 2002. Debugging the lungs: the use of therapeutic aerosols in the treatment of pulmonary infectious diseases. In S.R. Smith, F. Paul-Aviles, and J. Liu, eds. Pharmaceutical Approaches to Infectious Disease Therapy. Davis Horwood International, Godalming, UK, 67-93.
5. Prober, C.G., P.D. Walson, and J. Jones. 2000. Technical report: Regarding the use of aerosolized antibiotics. Pediatrics 106:89-94.
6. Zithromax package insert [On-line]. Available at: Accessed November 11, 2004. 〈http://www.fda.gov/ cder/foi/label/2000/50662S291bl.pdf.〉
7. Griffith, D.E., B.A. Brown, W.M. Girard, et al. 2001. Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease. Clin. Infect. Dis. 32:1547-1553.
8. Saiman, L., B.C. Marshall, N. Mayer-Hamblett, et al. 2003. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290:1749-1756.
9. Ekici, A., M. Ekici, and A.K. Erdemoglu. 2002. Effect of azithromycin on the severity of bronchial hyperresponsiveness in patients with mild asthma. J. Asthma 39:181-185.
10. French, A.L., Benator, D.A., and Gordin, P.M. 1997. Nontuberculosis mycobacterial infections. Med. Clin. North Am. 81:361-379.
11. Havlir, D.V., M.P. Dube, F.R. Sattler, et al. 1996. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N. Engl. J. Med. 335:392-398.
12. Oldfield, E.C., III, W.J. Fessel, M.W. Dunne, et al. 1998. Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial. Clin. Infect. Dis. 26:611-619.
13. Klemens, S.P., and M.H. Cynamon. 1994. Activities of azithromycin and clarithromycin against nontuberculous mycobacteria in beige mice. Antimicrob. Agents Chemother. 38:1455-1459.
14. Dunne, M.W., S. Bozzette, J.A. McCutchan, et al. 1999. Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: a randomised trial. California Collaborative Treatment Group. Lancet 354:891-895.
15. Brown, B.A., D.E. Griffith, W. Girard, et al. 1997. Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease. Clin. Infect. Dis. 24:958-964.
16. Amsden, G.W. 2005. Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions. JAC 55:10-21.
17. Garcia Contreras, L., and A.J. Hickey, 2002. Pharmaceutical and biotechnological aerosols for cystic fibrosis therapy. Adv. Drug Del. Rev. 54:1491-1504.
18. Garcia Contreras, L., and A.J. Hickey, 2003. Aerosol treatment of cystic fibrosis. Crit. Rev. Ther. Drug Carrier Sys. 20:317-356.
19. Hickey, A.J., and A.B. Montgomery, 2004. Aerosolized pentamidine for treatment and prophylaxis of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. In Pharmaceutical Inhalation Aerosol Technology, 2nd ed. Drug and Pharmaceutical Sciences, vol. 134. Marcel Dekker, New York, 459-172.
20. Iseman, M.D., 2002. Medical management of pulmonary disease caused by Mycobacterium avium complex. Clin. Chest Med. 23:633-641.
21. Thomas, C.F., Jr. and A.H. Limper. 2004. Medical progress: pneumocystis pneumonia. N. Engl. J. Med. 350:2487-2498.
22. Tanaka, E., R. Amitani, A. Niimi, et al. 1997. Yield of computed tomography and bronchoscopy for the diagnosis of Mycobacterium avium complex pulmonary disease. Am. J. Respir. Crit. Care Med. 155:2041-2046.
23. Miszkiel, K.A., A.U. Wells, M.B. Rubens, et al. 1997. Effects of airway infection by Pseudomonas aeruginosa: a computed tomographic study. Thorax 52:260-264.